ABT-080

• Description :

  ABT-080 is an orally active inhibitor of leukotriene biosynthesis. ABT-080 simultaneously blocks the leukotriene pathways leading to the synthesis of LTB4 and LTC4, but does not inhibit PGH2 biosynthesis. ABT-080 can block bronchoconstriction and be used in the research of asthma and related inflammations[1]

• Product Name Alternative :

  VML-530

• UNSPSC :

  12352005

• Target :

  Leukotriene Receptor

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/abt-080.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(CCC(C)(C1=CC=C(C=C1)OCC2=NC3=CC=CC=C3C=C2)C4=CC=C(C=C4)OCC5=NC6=CC=CC=C6C=C5)O[Na]

• Molecular Formula :

  C37H31N2NaO4

• Molecular Weight :

  590.64

• References & Citations :

  [1]Kolasa T, et al. Symmetrical bis (heteroarylmethoxyphenyl) alkylcarboxylic acids as inhibitors of leukotriene biosynthesis. J Med Chem. 2000 Aug 24;43 (17) :3322-34.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• CAS Number :

  [189498-57-5]